Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several label-supported claims are accurate (indications, prodrug/mechanism, common adverse reactions category, RLS timing concept). However, multiple important dosing discrepancies (especially PHN dosing) and an unsupported/incorrect dosing-administration detail for RLS reduce alignment.
Category Scores
Accurate Statements
Horizant is not classified as a controlled substance.
Not supported or contradicted by the provided label excerpts.
Horizant is a prodrug of gabapentin.
Label 12.1: “Gabapentin enacarbil is a prodrug of gabapentin...” and warnings section: “HORIZANT is a prodrug of gabapentin.”
Horizant works by affecting chemicals and nerves in the body involved in causing seizures and some types of pain.
Label 12.1: “...therapeutic effects in RLS and PHN are attributable to gabapentin.” (Mechanism described at label level as therapeutic effects attributable to gabapentin; no detailed “chemicals” wording provided.)
Horizant is prescribed for moderate-to-severe primary restless legs syndrome.
Label 1: “...indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults.”
Horizant is prescribed for postherpetic neuralgia.
Label 1: “...indicated for the management of postherpetic neuralgia (PHN) in adults.”
Horizant is an extended-release formulation of gabapentin enacarbil.
Label 12.3: “HORIZANT is an extended-release formulation of gabapentin enacarbil...”
Horizant is converted to gabapentin in the body.
Label 12.1/Warnings: “prodrug of gabapentin” and effects attributable to gabapentin.
The dosage for Horizant for restless legs syndrome is 600 mg taken once daily approximately one hour before bedtime.
Label 2.2: “600 mg once daily at about 5 PM.” (Label does not mention “one hour before bedtime.”)
Dosing of Horizant may be adjusted by a healthcare professional based on individual patient response and tolerability.
Label 2.4: “Dosing of HORIZANT is adjusted in accordance with renal function...” (No explicit label language about titration by response/tolerability for general use beyond timing and renal adjustment in provided excerpts.)
Horizant is a prescription medication.
Not supported or contradicted by the provided label excerpts.
Horizant should be used under the guidance of a qualified healthcare professional.
Not supported or contradicted by the provided label excerpts.
Horizant’s extended-release nature allows for less frequent dosing.
Partially implied by “extended-release” and label dosing once daily (RLS) / twice daily (PHN), but no explicit statement that it “allows for less frequent dosing” is provided in excerpts.
Common side effects of Horizant include dizziness.
Label 6.1: “...most commonly observed... somnolence/sedation and dizziness...” and warnings: “Somnolence/sedation and dizziness.”
Common side effects of Horizant include fatigue.
Not supported in provided excerpts as a “common” adverse reaction.
Common side effects of Horizant include nausea.
Not supported in provided excerpts as “common.” (Nausea is mentioned in morphine interaction language, not as common in provided trials excerpt.)
Common side effects of Horizant include somnolence.
Label 6.1: “...somnolence/sedation...” and warnings 5.1/5.2.
Horizant is manufactured by Amneal Pharmaceuticals.
Not supported or contradicted by the provided label excerpts.
Unsupported Statements
Horizant is not classified as a controlled substance.
Provided label excerpts do not address controlled substance classification.
Horizant works by affecting chemicals and nerves in the body involved in causing seizures and some types of pain.
Provided label excerpts do not describe “chemicals” or “nerves” in these terms; only prodrug/therapeutic effects attribution to gabapentin in RLS and PHN is shown.
Horizant is prescribed for moderate-to-severe primary restless legs syndrome.
The typical dosage for Horizant for restless legs syndrome is 600 mg taken once daily approximately one hour before bedtime.
Label specifies “about 5 PM” (does not state “one hour before bedtime”).
The dosage for Horizant for postherpetic neuralgia is 600 mg taken once daily.
Label 2.3 states PHN recommended dosage is 600 mg twice daily, with initiation at 600 mg in the morning for 3 days then increased to 600 mg twice daily.
Dosing of Horizant may be adjusted by a healthcare professional based on individual patient response and tolerability.
Provided excerpts primarily specify timing and renal-function-based dose adjustment; no label language in excerpts supports general response/tolerability-based adjustment.
Common side effects of Horizant include fatigue.
Not listed as one of the most commonly observed adverse reactions in provided label excerpts (somnolence/sedation and dizziness are).
Common side effects of Horizant include nausea.
Provided excerpts do not list nausea as among the most commonly observed adverse reactions; nausea is mentioned in morphine conjunction language, not as common.
Horizant’s extended-release nature allows for less frequent dosing.
No explicit label statement in provided excerpts connecting extended-release to “less frequent dosing.”
Horizant is a prescription medication.
Provided label excerpts do not explicitly state prescription-only status.
Horizant should be used under the guidance of a qualified healthcare professional.
Provided label excerpts do not explicitly state this counseling/requirement in those terms.
Horizant is manufactured by Amneal Pharmaceuticals.
Manufacturer information is not present in provided excerpts.
Horizant is not substitutable with other gabapentin products because of differing pharmacokinetic profiles [see Warnings and Precautions (5.3)].
This claim was not actually made in the listed AI claims; included here only if present—otherwise omit.
Contradictions
High
AI Statement
The dosage for Horizant for postherpetic neuralgia is 600 mg taken once daily.
Label Reference
Label 2.3: “The recommended dosage of HORIZANT is 600 mg twice daily.” and initiation instructions.
Important Omissions
For PHN, initiation and escalation are specified: start 600 mg in the morning for 3 days then increase to 600 mg twice daily on day four; also guidance for missed dose: skip if missed and take next scheduled dose.
Importance:
High
RLS dosing timing uses “about 5 PM” (not “one hour before bedtime”) and missing-dose instruction: if dose not taken at recommended time, take next dose following day as prescribed.
Importance:
Moderate
Administration instructions: tablets should be swallowed whole and should not be cut, crushed, or chewed; tablets should be taken with food.
Importance:
Moderate
Warnings include not driving until adequate experience is gained; also somnolence/sedation and dizziness with driving impairment. The AI did not mention driving guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
A clear contradiction exists for PHN dosing frequency (once daily stated vs twice daily per label). Additional omission of PHN titration/escalation and missed-dose handling may affect safe use. Other claims largely align (prodrug, indications, and common somnolence/dizziness).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Incorrect PHN dosing regimen (stated 600 mg once daily vs label 600 mg twice daily with 3-day morning-initiation).
Suggested Improvement
Correct PHN dosage and initiation schedule per label (600 mg twice daily; start 600 mg in the morning for 3 days then increase on day four). For RLS, use label timing (“about 5 PM”) and include correct tablet administration instructions (swallow whole; do not cut/crush/chew; take with food) plus driving impairment counseling.